Description: Humalog 100IU is a pharmaceutical product containing insulin lispro as its active ingredient. It is a rapid-acting insulin analog used in the management of diabetes mellitus. Humalog 100IU is available in various formulations, including vials and prefilled insulin pens, to facilitate subcutaneous injection.

Composition: Each milliliter (mL) of Humalog 100IU contains insulin lispro at a concentration of 100 units. The formulation may also contain excipients to adjust pH, enhance stability, and aid in injection.

Active Ingredient: Insulin lispro is a rapid-acting insulin analog designed to mimic the natural physiological response of insulin secretion following meals. It has a rapid onset of action, reaching peak blood levels within 30 to 90 minutes after injection, and a shorter duration of action compared to regular human insulin.

Uses: Humalog 100IU is indicated for the treatment of diabetes mellitus in adults and children. It is used to control hyperglycemia (high blood sugar levels) by replacing or supplementing endogenous insulin production. Humalog is typically administered shortly before or immediately after meals to help regulate postprandial glucose levels.

Usage and Dosage: The dosage and administration of Humalog 100IU should be individualized based on factors such as the patient’s blood glucose levels, dietary intake, and insulin sensitivity. It is usually administered subcutaneously into the abdominal wall, thigh, or upper arm. Dosage adjustments may be necessary depending on the patient’s response and changes in insulin requirements.

Storage Conditions: Humalog 100IU should be stored according to the manufacturer’s instructions. Unopened vials or insulin pens should be refrigerated between 2°C to 8°C (36°F to 46°F). Once opened, they can be kept at room temperature (below 30°C or 86°F) for up to 28 days. Insulin should not be frozen or exposed to direct heat or sunlight.

Mechanism of Action: Insulin lispro acts similarly to endogenous insulin by binding to insulin receptors on target cells, such as muscle and fat cells, and promoting glucose uptake and utilization. Its rapid onset of action helps to control postprandial glucose levels by facilitating the entry of glucose into cells, thereby lowering blood sugar concentrations.

Contraindications: Humalog 100IU is contraindicated in patients with hypoglycemia (low blood sugar) or hypersensitivity to insulin lispro or any components of the formulation. It should not be used during episodes of hypoglycemia or in insulin infusion pumps.

Adverse Reactions: Common adverse reactions associated with Humalog 100IU may include hypoglycemia, injection site reactions (such as pain, redness, or swelling), weight gain, and allergic reactions. Patients should be educated about the signs and symptoms of hypoglycemia and instructed on proper injection techniques to minimize adverse effects.

Patients should consult with their healthcare provider for personalized information regarding the use of Humalog 100IU, including dosage adjustments, injection technique, and management of hypoglycemic episodes. Regular monitoring of blood glucose levels and close medical supervision are essential for safe and effective diabetes management.